In Brief: Texas Biotechnology Novastan
Executive Summary
Texas Biotechnology Novastan: Rolling NDA submission for argatroban begins June 27 for anticoagulant in treatment of heparin-induced thrombocytopenia; submission will be completed in August. Novastan is also being evaluated as an adjunct to thrombolytics for acute myocardial infarction...